NOXXON Pharma: KOL Webinar on GLORIA Top-Line Results of NOX-A12 & Radiotherapy Combination in First-Line Glioblastoma Presented at ASCO 2022
|DATE:||June 10, 2022|
|TIME:||8:00 AM EDT|
About The Event
The webinar will feature a presentation from Frank A. Giordano, M.D. (Chair, Department of Radiation Oncology, University Hospital Bonn, Germany), who will present and discuss the top-line results of the GLORIA Phase 1/2 trial evaluating NOX-A12 in combination with radiotherapy in patients with newly diagnosed glioblastoma and unmethylated MGMT promoter.
The webinar will follow Dr. Giordano’s poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that will take place from June 3-7, 2022, in Chicago, Illinois, US. Dr. Giordano will discuss the top-line results based on 6-month therapy of patients treated in the GLORIA study that complement the recently reported positive data.
NOX-A12 is an inhibitor of the chemokine CXCL12 and has been granted orphan drug status in the US and EU for the treatment of certain brain cancers and produced promising clinical data thus far. Dr. Giordano will be available for questions following the formal presentation.